The trial has recruited patients from 36 centers across Europe.
This double blind trial is comparing two doses of TB-402 (25mg and 50mg), given as a single intravenous infusion after total hip replacement, with the r factor Xa inhibitor rivaroxaban.
TB-402 partially inhibits factor VIII, a key component of the coagulation cascade.
ThromboGenics CEO Patrik De Haes said that VTE remains a significant unmet need in many clinical settings despite the introduction of a number of new anticoagulants.